PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Autoimmun. Author manuscript; available in PMC 2009 August 1.
Published in final edited form as:
PMCID: PMC2465466
NIHMSID: NIHMS56393

Extreme Genetic Risk for Type 1A Diabetes in the Post-Genome Era

Abstract

A series of genes and loci influencing the genetic risk of type 1A (immune-mediated) diabetes are now well characterized. These include genes of the major histocompatibility complex (MHC), polymorphisms 5′ of the insulin gene, and PTPN22, as well as more recently defined loci from genome-wide association studies. By far the major determinants of risk for type 1A diabetes are genes within or linked to the MHC and in particular alleles of class II genes (HLA-DR, DQ, and DP). There is evidence that MHC class I alleles contribute and there are additional MHC-linked influences such that for a major subset of relatives of patients there is a risk as high as 80% for siblings, and for the general population a risk as high as 20% can be defined at birth just by analyzing the MHC. We believe the search for additional MHC loci will require analysis of the remarkable long-range identity (up to 9 million base pairs) of extended MHC haplotypes. Current prediction algorithms will likely be greatly improved for the general population when the additional contributing loci of the MHC are defined.

Keywords: autoimmunity, HLA, Type 1 Diabetes

Introduction

Multiple genetic syndromes are associated with the development of immune mediated diabetes of man. In particular, there are two rare “monogenic disorders” that provide important insight into pathways leading to autoimmune destruction of islet beta cells: IPEX (Immune dysfunction, Polyendocrinopathy, Enteropathy, X-linked) and APSI (Autoimmune Polyendocrine Syndrome Type 1) syndromes. IPEX syndrome results from mutations of the FOXP3 gene leading to a lack of a major population of regulatory T lymphocytes with resulting overwhelming autoimmunity and development of diabetes in approximately 80% of the children with this disorder. Diabetes can occur as early as two days of age. For the APS-I syndrome, and the related mouse model with mutations of the AIRE (Autoimmune Regulator) gene, it is hypothesized that abnormalities in expression of peripheral antigens within the thymus and/or abnormalities of negative selection result in widespread autoimmunity. Approximately 18% of children with this syndrome develop type 1A diabetes.

The more common type 1A diabetes is a “polygenic” disorder primarily determined by genes within or linked to the major histocompatibility complex (MHC).

Multiple Genes Determining Susceptibility

Type 1A diabetes has a strong genetic component. First degree relatives have a higher risk for type 1A diabetes than the general population, and siblings have a higher risk than offspring. The sibling relative risk for type 1A diabetes is 15 (λS, a measure of familial clustering) [1].

The Major Histocompatibility Complex

HLA-DR/DQ

The class II loci HLA-DRB1 and HLA-DQB1 in the MHC are known to be associated with type 1A diabetes risk based on functional, structural and genetic evidence [2]. DR3-DQA1*0501-DQB1*0201 (DR3) and DR4-DQA1*0301-DQB1*0302 (DR4) are the highest risk DR/DQ haplotypes for type 1A diabetes, and 30–40% of type 1A diabetes patients have the heterozygous genotype DR3/4 [2,3]. Of the general population children in Denver, 2.4% carry this genotype, and these individuals have an absolute risk of approximately 1/15 versus a risk of 1/300 in the general population [3]. In contrast to lower risk homozygous DR4/4 or DR3/3 genotypes, the increased type 1A diabetes risk of DR3/4 individuals is probably a result of DQ alpha and beta heterodimers that form in DR3/4 individuals. In particular, it is hypothesized that the DQA1*0501 on DR3 haplotypes combining with the DQB1*0302 allele on DR4 haplotypes is most important, as that rare African DRB1*0405 haplotypes with DQA1*0301-DQB1*0201 alleles in cis (same as the alternate trans heterodimer of DR3/4 individuals) are lower risk than DQA1*0301-DQB1*0302 haplotypes [4].

Risk of diabetes is influenced by both DRB1*04 variants and DQ alleles on DR4 haplotypes (Table 1) [4]. Thus there is a hierarchy of DRB1*04 haplotypes, even with the same DQA1*0301-DQB1*0302 alleles, with higher risk from DRB1*0405 (OR=11.4), DRB1*0401 (OR=8.4), DRB1*0402 (OR=3.6), and DRB1*0404 (OR=1.6), while DRB1*0403 is protective (OR=0.27). Similarly, for DRB1*0401, variation of DQB1 influences risk, as haplotypes with DQB1*0302 (OR=8.4) are highly susceptible, while those with DQB1*0301 (OR=0.35) are modestly protective. The influence of DRB1*04-DQ haplotypes on diabetes risk is complex and influenced by genotype, as the proportion of DQB1*0301 is greater in DR1/4 patients (13.1%) than in DR3/4 (0.7%) patients and, additionally within these genotypes, there is a different distribution of DRB1*0401 alleles [4]. There are several DQ risk alleles with aspartic acid at position 57 and these alleles are particularly prominent in the Asian patients, but are also determinants of risk in Caucasian populations [4].

Table 1
Legend: HLA-DRB1*04 and DQB1 effects on type 1A diabetes risk [4]

There are dramatically protective DR-DQ haplotypes [e.g. DRB1*1501-DQA1*0102-DQB1*0602 (OR=0.03), DRB1*1401-DQA1*0101-DQB1*0503 (OR=0.02) and DRB1*0701-DQA1*0201-DQB1*0303 (OR=0.02)]. The most common is the DR2 (DRB1*1501) bearing haplotype. The DR2 haplotype (DRB1*1501-DQA1*0102-DQB1*0602) is dominantly protective (20% of general population individuals have DQB1*0602 but it is present in only 1% of type 1A diabetes patients) [5]. At present, it is not settled as to why a small subset of children with DQB1*0602 still develop type 1A diabetes, but there are reports of genetic heterogeneity at other MHC loci [6,7]

HLA-DP

HLA-DPB1 alleles have been reported to be associated with type 1A diabetes, but are not generally recognized as major contributors to type 1A diabetes [8]. Several groups have reported a negative association of DPB1*0402 with type 1A diabetes [915]. These studies have found that the frequency of the DPB1*0402 allele is lower in patients than in control groups and that transmission of DPB1*0402 to type 1A diabetes patients is decreased. On average, the relative risk for DPB1*0402 overall from these studies is 0.56. DPB1*0301 and DPB1*0202 have been reported to be predisposing to type 1A diabetes.

Class I and Class III MHC

HLA-A is associated with type 1A diabetes independent of DR/DQ [16]. A24 is associated with a younger age of onset, A30 (typically on the DR3-B18-A30 haplotype) is higher risk, and A1 (typically on the DR3-B8-A1 haplotype) is lower risk than other DR3 haplotypes [16]. HLA-B and HLA-C alleles are also associated with type 1A diabetes independent of DR/DQ [17]. HLA-B18, B39, B44, C3, C8 and C16 are associated with type 1A diabetes and with age of onset after adjustment for linkage disequilibrium with DR/DQ [17]. Nejentsev et al. used a recursive partitioning, a risk-categorization method of grouping that doesn’t require the risk to be known a priori, to correct for HLA alleles [18]. They concluded that both HLA-A and HLA-B survive correction for HLA-DR and DQ, and that in particular HLA-B39 is important (confers high risk for type 1A diabetes in three different populations), makes up the majority of the signal from HLA-B, and is associated with a lower age of onset of the disease [18]. MICA is reported to be associated with type 1A diabetes when the DR/DQ genotype is fixed (within DR3/4 siblings and offspring) [19].

Extended MHC Haplotypes

The MHC region exhibits strong and extended linkage disequilibrium, and it has been known for years that these haplotypes can be identical for up to 3.2 Mb, from HLA-DRB1 to HLA-A, with one report describing conservation for 6–8 Mb telomeric from HLA-DRB1 [20]. Such extended HLA haplotypes make it difficult to define specific loci that contribute to diabetes risk beyond HLA alleles. Detection of this conservation has been based on microsatellite data, complement gene typing, and HLA-DR/DQ, HLA-B, HLA-C and HLA-A alleles [2023]. One recent article reports that slightly more than half of Caucasian MHC haplotypes (based on complement alleles, HLA-B and HLA-DR/DQ typing) are fixed from HLA-DR/DQ to HLA-B [24]. Extreme variability in the MHC class III region has been identified using SNP typing [25].

DR3-B8-A1 (8.1)

The DR3-B8-A1 haplotype is extremely conserved [≥99% identity of single nucleotide polymorphisms (SNPs)] [26]. This extreme conservation can extend for up to 9 Mb, from HLA-DRB1 through the 3 Mb of the MHC region and to the telomeric end of the extended MHC (23 Mb from the chromosome 6 telomere) [27]. The DR3-B8-A1 haplotype is the most common extended haplotype, as it is present in 9% of Caucasian MHC control haplotypes and 18% of case MHC haplotypes from individuals with type 1A diabetes [24].

Other Extended Haplotypes

In addition to the DR3-B8-A1 haplotype, other extended HLA haplotypes have been identified [22,24,25,28]. These haplotypes are common, conserved (based on complement alleles and HLA typing) and extend from DRB1 to HLA-A [24,29].

Non-MHC Genes

Insulin Gene

A VNTR (variable number tandem repeats) microsatellite at the 5′ end of the insulin gene (INS) on chromosome 11 has alleles that are functionally associated with both type 1A diabetes risk and protection, with an allelic odds ratio (from a genome-wide linkage scan) of 1.9 [3032]. Two groups provided evidence that the allelic variant associated with protection from type 1A diabetes was associated with greater expression of insulin messenger RNA within the thymus [31,33]. Studies in the NOD mouse model of type 1A diabetes implicate insulin/proinsulin as the primary autoantigen where decreased insulin expression in the thymus also correlates with risk [34], induction of tolerance to proinsulin prevents both diabetes and development of T cells reacting with the islet target molecule IGRP [35], and mutating a key amino acid of insulin peptide B:9–23 prevents diabetes [36,37].

PTPN22

A gene at 1p13, PTPN22, encodes for LYP (a protein tyrosine phosphatase). Multiple groups have reported an association with type 1A diabetes of a nonsynonymous SNP in PTPN22 at position 1858, with an odds ratio of 3.4 for the homozygous TT genotype [38,39] in many different populations [40] and the same polymorphism is a major determinant of rheumatoid arthritis [41,42] and other autoimmune disorders [43]. The polymorphism changes an arginine at position 620 to a tryptophan and has been associated with a gain of function [44]. It is of interest that the risk allele of PTPN22 apparently decreases T cell receptor signaling, suggesting that the risk allele may influence autoimmunity by decreasing negative T cell selection within the thymus that is dependent upon strong T cell receptor activation.

Other Defined Loci

A genome-wide association study for type 1A diabetes was completed in 2007 by the Wellcome Trust Case Control Consortium, reporting signals at known loci [6p21 (MHC region), 11q15 (INS), 2q33 (CTLA4), 1p13 (PTPN22), 10p15 (CD25/IL2RA) and 2q24 (IFIH1)] in addition to SNP associations at several novel loci (12q13, 12q24, 16p13, 4q27, 12p13 and 18p11) [45]. The associations at 12q24, 12q13, 16p13 and 18p11 were confirmed in an independent study (Figure 1) [46].

Figure 1
Odds ratios for the susceptibility allele for the ten independent confirmed type 1A diabetes-associated genes or regions; Adapted by permission from Macmillan Publishers Ltd: Nature Genetics [46], © 2007

CTLA4, at 2q33, has an odds ratio of 1.1–1.2, but the association has been replicated in multiple studies [30,47]. The CTLA4 locus is of interest given the role of CTLA4 in T cell signaling. The locus is associated primarily with patients with both thyroid autoimmunity and type 1A diabetes, concordant with its stronger association with thyroid autoimmunity [48].

Prior to the large whole genome association studies recently reported, other associations have been reported for CD25/IL2RA (10p15), SUMO4 (6q25), and IFIH1 (2q24), in addition to other loci [4952]. Of these three genes, the clearest confirmation is for CD25/IL2RA (10p15), with the finding of more than one CD25 SNP associated with type 1A diabetes (Figure 1). The CD25/IL2RA locus is implicated in a number of autoimmune disorders including multiple sclerosis, but in that case a different SNP is associated with increased risk. The CD25 SNPs that are associated with risk of type 1A diabetes are associated with differences in circulating levels of CD25, which despite extensive overlap between levels, is highly significant when a large number of individuals are studied [50]. The mechanism by which the SNPs contribute to diabetes risk is currently unknown, and may be complex given two associated SNPs in the same locus, neither of which alters the coding sequence.

Extreme Genetic Risk

Monozygotic Twins of Patients with Type 1A Diabetes

In a study of 44 monozygotic and 183 dizygotic twin pairs from the Finnish Twin Cohort the 10-year progression rate to diabetes for monozygotic (MZ) twin-mates was 33%, whereas dizygotic (DZ) twin-mates only had a risk of 3% [53]. The study reported probandwise concordance rates of 42.9% for MZ twins and 7.4% for DZ twins [53]. In addition, they reported that an additive model was the best fit for type 1A diabetes risk, suggesting that 88% of phenotypic variance in type 1A diabetes is due to additive genetic effects and 12% is due to environmental factors [53]. Furthermore, a study describing MZ twins in the United States and Great Britain confirmed this high risk, concluding that the risk for type 1A diabetes, by survival analysis, was 39% for the initially discordant twin at 40 years of discordance [54].

DR3/4 Relatives of Patients with Type 1A Diabetes

The Diabetes Autoimmunity Study of the Young (DAISY), with principal investigator Marian Rewers, has HLA-typed more than 30,000 newborns and followed more than 2,000 increased risk children from birth (both general population children and relatives of patients with type 1A diabetes). The cumulative incidence of developing expression of persistent anti-islet autoantibodies by age 7 for DAISY DR3/4 siblings of patient with type 1A diabetes is 41%, 16% for DR3/4 offspring of patients with type 1A diabetes, and general population DR3/4 individuals have a 5% cumulative incidence [55].

DAISY DR3/4 siblings can share 0, 1 or 2 haplotypes identical by descent with their proband sibling [55]. DR3/4 siblings that share both haplotypes identical by descent with the proband had a risk of 63% for developing anti-islet autoantibodies by age 7 and 85% by age 15, whereas siblings that share 0 or 1 haplotypes with the proband had a risk of 20% of developing anti-islet autoantibodies [55] (Figure 2) and a concordant risk of progression to type 1A diabetes. The observation that there is a large difference in risk between DR3/4 siblings sharing 2 haplotypes identical by descent and those sharing 0 or 1 indicates that there are additional non-DR/DQ loci in or linked to the MHC that contributes to type 1A diabetes risk [55]. “Fixing” only MHC loci can determine extreme genetic risk.

Figure 2
Extreme risk for Diabetic Autoimmunity in DR3/4 Siblings: haplotype sharing effects on progression to antibodies and type 1 diabetes; Modified from Aly et al. PNAS 2006 [55] diamonds and solid line: siblings at high risk (share 2 haplotypes) squares and ...

Ziegler and coworkers have reported that DR3/4 individuals with two first degree relatives with type 1A diabetes also have an extreme risk of developing islet autoimmunity and diabetes [56]. For example, if both parents of a child have type 1A diabetes and the child has the DR3/4 genotype, then both the DR3 and DR4 haplotypes by “necessity” are derived from an affected parent. Both haplotypes are present in a proband, and thus is similar to the sibling algorithm of the DAISY study (see above).

DR3/4 General Population Children

The vast majority of individuals who develop type 1A diabetes do not have a first degree relative with the disorder (>85%). Extending the ability to identify extreme risk to the general population without a relative with type 1A diabetes is thus an important goal. In DAISY DR3/4 general population children there is a protective effect of the HLA-DPB1*0402 allele (Figure 3). DR3/4 children without the protective DPB1*0402 allele have a risk of anti-islet autoimmunity of almost 20% [57].

Figure 3
Protective effects of HLA-DPB1*0402 in DAISY DR3/4 general population children: progression to autoantibodies and type 1 diabetes; Copyright © 2008 American Diabetes Association From Diabetes®, Vol. 56, 2007; 2405–2409. Reprinted ...

Environmental Factors Affecting Type 1A Diabetes Susceptibility

There is compelling evidence that the incidence of type 1A diabetes is doubling approximately every 20 years in developed countries [58,59], and thus environmental factors are of importance. Environmental determinants of type 1A diabetes are likely to be common, given the ability to define high genetic risk (perhaps similar to celiac disease with almost universal exposure to a dietary inciting factor, gliadin) [60]. A recent report implicates decreased omega-3 polyunsaturated fatty acid ingestion with type 1A diabetes risk [61], and a large trial is evaluating exclusion of bovine milk from infant diets following completion of a pilot study [62]. Though diet may influence development of anti-islet autoimmunity, the leading hypothesis for the increasing incidence of type 1A diabetes is similar to that for many immune mediated disorders, namely the “hygiene hypothesis”, postulating decreased pathogen exposure contributes to increased autoimmunity [63].

Conclusion

With the advent of whole-genome SNP genotyping studies in the past several years, many additional non-MHC loci have been identified that contribute to type 1A diabetes risk. In addition, non-DR/DQ loci within the MHC have been identified that contribute to prediction of type 1A diabetes in the general population (i.e. HLA-DP). These will allow for the potential to identify individuals at extreme risk for type 1A diabetes at birth, and currently clinical trials are forming to prevent disease prior to the onset of autoimmunity in genetically susceptible individuals (i.e. Pre-Point). Intervention prior to the onset of autoimmunity may be key, as it has proven difficult to turn off the autoimmune process once it begins.

Acknowledgments

This work is supported by grants from the National Institutes of Health (DK32083, DK55969, DK62718, AI50864, DK32493, DK064605), the Diabetes Endocrine Research Center grant from the National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK57516), the American Diabetes Association, the Juvenile Diabetes Foundation (JDRF1-2006-16), and the Children’s Diabetes Foundation.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Risch N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet. 1987;40:1–14. [PubMed]
2. She J-X. Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol Today. 1996;17:323–329. [PubMed]
3. Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, McDuffie RS, Jr, Hamman RF, Klingensmith G, Eisenbarth GS, Erlich HA. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY) Diabetologia. 1996;39:807–812. [PubMed]
4. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, Mychaleckyj JC, Todd JA, Bonella P, Fear AL, Lavant E, Louey A, Moonsamy P. HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk: Analysis of the Type 1 Diabetes Genetics Consortium Families. Diabetes. 2008 Epub Ahead of Print. [PubMed]
5. Redondo MJ, Fain PR, Eisenbarth GS. Genetics of type 1A diabetes. Recent Prog Horm Res. 2001;56:69–89. [PubMed]
6. Husain Z, Kelly MA, Eisenbarth GS, Pugliese A, Awdeh ZL, Larsen CE, Alper CA. The MHC type 1 diabetes susceptibility gene is centromeric to HLA-DQB1. J Autoimmun. 2007 Epub Ahead of Print. [PubMed]
7. Valdes AM, Thomson G, Graham J, Zarghami M, McNeney B, Kockum I, Smith A, Lathrop M, Steenkiste AR, Dorman JS, Noble JA, Hansen JA, Pugliese A, Lernmark A. D6S265*15 marks a DRB1*15, DQB1*0602 haplotype associated with attenuated protection from type 1 diabetes mellitus. Diabetologia. 2005;48:2540–2543. [PubMed]
8. Easteal S, Kohonen-Corish MR, Zimmet P, Serjeantson SW. HLA-DP variation as additional risk factor in IDDM. Diabetes. 1990;39:855–857. [PubMed]
9. Baisch JM, Capra JD. Analysis of HLA genotypes and susceptibility to insulin-dependent diabetes mellitus: association maps telomeric to HLA-DP. Scand J Immunol. 1992;36:331–340. [PubMed]
10. Erlich HA, Rotter JI, Chang JD, Shaw SJ, Raffel LJ, Klitz W, Bugawan TL, Zeidler A. Association of HLA-DPB1*0301 with IDDM in Mexican-Americans. Diabetes. 1996;45:610–614. [PubMed]
11. Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: Molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet. 1996;59:1134–1148. [PubMed]
12. Lie BA, Akselsen HE, Joner G, Dahl-Jorgensen K, Ronningen KS, Thorsby E, Undlien DE. HLA associations in insulin-dependent diabetes mellitus: no independent association to particular DP genes. Hum Immunol. 1997;55:170–175. [PubMed]
13. Noble JA, Valdes AM, Thomson G, Erlich HA. The HLA class II locus DPB1 can influence susceptibility to type 1 diabetes. Diabetes. 2000;49:121–125. [PubMed]
14. Cucca F, Dudbridge F, Loddo M, Mulargia AP, Lampis R, Angius E, De Virgiliis S, Koeleman BP, Bain SC, Barnett AH, Gilchrist F, Cordell H, Welsh K, Todd JA. The HLA-DPB1--associated component of the IDDM1 and its relationship to the major loci HLA-DQB1, -DQA1, and -DRB1. Diabetes. 2001;50:1200–1205. [PubMed]
15. Cruz TD, Valdes AM, Santiago A, Frazer dL, Raffel LJ, Ziedler A, Rotter JI, Erlich HA, Rewers M, Bugawan T, Noble JA. DPB1 alleles are associated with type 1 diabetes susceptibility in multiple ethnic groups. Diabetes. 2004;53:2158–2163. [PubMed]
16. Noble JA, Valdes AM, Bugawan TL, Apple RJ, Thomson G, Erlich HA. The HLA class I A locus affects susceptibility to type 1 diabetes. Hum Immunol. 2002;63:657–664. [PubMed]
17. Valdes AM, Erlich HA, Noble JA. Human leukocyte antigen class I B and C loci contribute to Type 1 Diabetes (T1D) susceptibility and age at T1D onset. Hum Immunol. 2005;66:301–313. [PubMed]
18. Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, Stevens HE, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature. 2007;450:887–892. [PMC free article] [PubMed]
19. Ide A, Babu SR, Robles DT, Wang T, Erlich HA, Bugawan TL, Rewers M, Fain PR, Eisenbarth GS. Homozygosity for premature stop codon of the MHC class I chain-related gene A (MIC-A) is associated with early activation of islet autoimmunity of DR3/4-DQ2/8 high risk DAISY relatives. J Clin Immunol. 2005;25:303–308. [PubMed]
20. Yunis EJ, Larsen CE, Fernandez-Vina M, Awdeh ZL, Romero T, Hansen JA, Alper CA. Inheritable variable sizes of DNA stretches in the human MHC: conserved extended haplotypes and their fragments or blocks. Tissue Antigens. 2003;62:1–20. [PubMed]
21. Cattley SK, Williamson JF, Tay GK, Martinez OP, Gaudieri S, Dawkins RL. Further characterization of MHC haplotypes demonstrates conservation telomeric of HLA-A: update of the 4AOH and 10IHW cell panels. Eur J Immunogenet. 2000;27:397–426. [PubMed]
22. Raum D, Awdeh Z, Yunis EJ, Alper CA, Gabbay KH. Extended major histocompatibility complex haplotypes in type I diabetes mellitus. J Clin Invest. 1984;74:449–454. [PMC free article] [PubMed]
23. Kruskall MS. The major histocompatibility complex: the value of extended haplotypes in the analysis of associated immune diseases and disorders. Yale J Biol Med. 1990;63:477–486. [PMC free article] [PubMed]
24. Alper CA, Larsen CE, Dubey DP, Awdeh ZL, Fici DA, Yunis EJ. The haplotype structure of the human major histocompatibility complex. Hum Immunol. 2006;67:73–84. [PubMed]
25. Smith WP, Vu Q, Li SS, Hansen JA, Zhao LP, Geraghty DE. Toward understanding MHC disease associations: Partial resequencing of 46 distinct HLA haplotypes. Genomics. 2006;87:561–571. [PubMed]
26. Aly TA, Eller E, Ide A, Gowan K, Babu SR, Erlich HA, Rewers MJ, Eisenbarth GS, Fain PR. Multi-SNP Analysis of MHC Region: Remarkable Conservation of HLA-A1-B8-DR3 Haplotype. Diabetes. 2006;55:1265–1269. [PubMed]
27. Aly TA, Baschal EE, Jahromi MM, Fernando MS, Babu SR, Fingerlin TE, Kretowski A, Erlich HA, Fain PR, Rewers MJ, Eisenbarth GS. Analysis of Single Nucleotide Polymorphisms Identifies Major Type 1A Diabetes Locus Telomeric of the Major Histocompatibility Complex. Diabetes. 2008;57:770–776. [PubMed]
28. Awdeh ZL, Raum D, Yunis EJ, Alper CA. Extended HLA/complement allele haplotypes: evidence for T/t-like complex in man. Proc Natl Acad Sci USA. 1983;80:259–263. [PubMed]
29. Romero V, Larsen CE, Duke-Cohan JS, Fox EA, Romero T, Clavijo OP, et al. Genetic fixity in the human major histocompatibility complex and block size diversity in the class I region including HLA-E.BMC. Genet. 2007;8:14. [PMC free article] [PubMed]
30. Concannon P, Erlich HA, Julier C, Morahan G, Nerup J, Pociot F, Todd JA, Rich SS. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes. 2005;54:2995–3001. [PubMed]
31. Pugliese A, Zeller M, Fernandez A, Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type I diabetes. Nat Genet. 1997;15:293–297. [PubMed]
32. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM) Am J Hum Genet. 1993;52:506–516. [PubMed]
33. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, Wickramasinghe S, Colle E, Polychronakos C. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet. 1997;15:289–292. [PubMed]
34. Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, Devendra D, Beilke J, Gianani R, Gill RG, Eisenbarth GS. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A. 2003;100:10376–10381. [PubMed]
35. Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, Colman PG, Harrison LC, Lew AM, Thomas HE, Kay TW. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest. 2006;116:3258–3265. [PMC free article] [PubMed]
36. Nakayama M, Beilke JN, Jasinski JM, Kobayashi M, Miao D, Li M, Coulombe MG, Liu E, Elliott JF, Gill RG, Eisenbarth GS. Priming and effector dependence on insulin B:9–23 peptide in NOD islet autoimmunity. J Clin Invest. 2007;117:1835–1843. [PMC free article] [PubMed]
37. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature. 2005;435:220–223. [PMC free article] [PubMed]
38. Zheng W, She JX. Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes. Diabetes. 2005;54:906–908. [PubMed]
39. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS, Comings D, Mustelin T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004;36:337–338. [PubMed]
40. Zoledziewska M, Perra C, Orru V, Moi L, Frongia P, Congia M, Bottini N, Cucca F. Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 diabetes. Diabetes. 2008;57:229–234. [PubMed]
41. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, et al. A Missense Single-Nucleotide Polymorphism in a Gene Encoding a Protein Tyrosine Phosphatase (PTPN22) Is Associated with Rheumatoid Arthritis. Am J Hum Genet. 2004;75:330–337. [PubMed]
42. Lee AT, Li W, Liew A, Bombardier C, Weisman M, Massarotti EM, Kent J, Wolfe F, Begovich AB, Gregersen PK. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun. 2005;6:129–133. [PubMed]
43. Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity. 2007;40:453–461. [PubMed]
44. Vang T, Congia M, Macis MD, Musumeci L, Orru V, Zavattari P, Nika K, Tautz L, Tasken K, Cucca F, Mustelin T, Bottini N. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet. 2005;37:1317–1319. [PubMed]
45. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–678. [PMC free article] [PubMed]
46. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39:857–864. [PMC free article] [PubMed]
47. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–511. [PubMed]
48. Howson JM, Dunger DB, Nutland S, Stevens H, Wicker LS, Todd JA. A type 1 diabetes subgroup with a female bias is characterised by failure in tolerance to thyroid peroxidase at an early age and a strong association with the cytotoxic T-lymphocyte-associated antigen-4 gene. Diabetologia. 2007;50:741–746. [PMC free article] [PubMed]
49. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39:1329–1337. [PMC free article] [PubMed]
50. Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, Bourget K, Plagnol V, Field S, Atkinson M, Clayton DG, Wicker LS, Todd JA. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet. 2007;39:1074–1082. [PubMed]
51. Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, et al. A functional variant of SUMO4, a new IkappaBalpha modifier, is associated with type 1 diabetes. Nat Genet. 2004;36:837–841. [PubMed]
52. Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, Guja C, Ionescu-Tirgoviste C, Widmer B, Dunger DB, Savage DA, Walker NM, Clayton DG, Todd JA. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet. 2006;38:617–619. [PubMed]
53. Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes. 2003;52:1052–1055. [PubMed]
54. Redondo MJ, Yu L, Hawa M, Mackenzie T, Pyke DA, Eisenbarth GS, Leslie RD. Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia. 2001;44:354–362. [PubMed]
55. Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, Yu L, Miao D, Erlich HA, Fain PR, Barriga KJ, Norris JM, Rewers MJ, Eisenbarth GS. Extreme Genetic Risk for Type 1A Diabetes. Proc Natl Acad Sci USA. 2006;103:14074–14079. [PubMed]
56. Bonifacio E, Hummel M, Walter M, Schmid S, Ziegler AG. IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care. 2004;27:2695–2700. [PubMed]
57. Baschal EE, Aly TA, Babu SR, Fernando MS, Yu L, Miao D, Barriga KJ, Norris JM, Noble JA, Erlich HA, Rewers MJ, Eisenbarth GS. HLA-DPB1*0402 Protects Against Type 1A Diabetic Autoimmunity in the Highest Risk DR3-DQB1*0201/DR4-DQB1*0302 DAISY Population. Diabetes. 2007;56:2405–2409. [PubMed]
58. Eurodiab ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group. Lancet. 2000;355:873–876. [PubMed]
59. Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith G, Bloch C, Rewers M, Dabelea D. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. Diabetes Care. 2007;30:503–509. [PubMed]
60. Dabelea D, Bell RA, D’Agostino RB, Jr, Imperatore G, Johansen JM, Linder B, Liu LL, Loots B, Marcovina S, Mayer-Davis EJ, Pettitt DJ, Waitzfelder B. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716–2724. [PubMed]
61. Norris JM, Yin X, Lamb MM, Barriga K, Seifert J, Hoffman M, Orton HD, Baron AE, Clare-Salzler M, Chase HP, Szabo NJ, Erlich H, Eisenbarth GS, Rewers M. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA. 2007;298:1420–1428. [PubMed]
62. Akerblom HK, Virtanen SM, Ilonen J, Savilahti E, Vaarala O, Reunanen A, et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia. 2005;48:829–837. [PubMed]
63. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347:911–920. [PubMed]